A global pharmaceutical company based in Europe forms in-licensing and partnering relationships with early stage therapeutic companies worldwide. The firm also has a corporate venture group which makes equity investments in early stage companies.
The firm’s focus areas are Cardiometabolic disease, CNS, Immunology, Oncology, and Respiratory diseases. Therapeutic opportunities beyond these focus areas may be considered by the corporate venture fund or by an internal research group, which assesses very early-stage emerging areas of science. The firm considers both small molecule and biologic assets but is generally not interested in cell therapy technologies. The firm prefers to consider assets that have attained proof of concept data (in vitro or in vivo) linking the treatment’s mechanism of action to the disease process.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment